证券代码：002020 证券简称：京新药业 公告编号：2026003 浙江京新药业股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）第九届董事会第三次 会议通知于 2026 年 1 月 7 日以电子邮件形式发出，会议于 2026 年 1 月 12 以电话及传真的方式召开。本次会议应参加表决的董事 9 名，实际参加表决 的董事 9 名，会议召开符合《公司法》和《公司章程》的规定。会议经表决 形成决议如下： 一、以 9 票同意、0 票反对和 0 票弃权的表决结果，审议通过了《关于 公司发行 H 股股票并在香港联合交易所有限公司上市的议案》； 为深化全球化战略布局，提高公司国际形象及综合竞争力，公司拟发行 境外上市股份（H 股）并申请在香港联交所主板挂牌上市（以下简称"本次 发行"或"本次发行并上市"）。 公司本次发行需在符合中国境内相关法律、法规和规范性文件、香港法 律的要求和条件下进行，并需取得中国证券监督管理委员会（以下简称"中 国证监会"）、香港联交所和香港证券及期货事务监察 ...

证券日报网讯1月12日，京新药业（002020）在互动平台回答投资者提问时表示，公司会依据相关法律 法规及公司信披管理制度，做好信息披露工作。 ...

（文章来源：证券日报） 证券日报网讯 1月12日，京新药业在互动平台回答投资者提问时表示，公司在努力推进地达西尼的销售 工作，可以贡献更好的业绩。具体数据敬请关注相关定期报告。 ...

资金流向方面，今日该股主力资金净流出5545.07万元，其中，特大单净流出4484.34万元，大单资金净 流出1060.73万元。近5日主力资金净流出6566.41万元。 融资融券数据显示，该股最新（1月9日）两融余额为4.41亿元，其中，融资余额为4.39亿元，融券余额 为236.73万元。近5日融资余额合计减少574.12万元，降幅为1.29%，融券余额合计增加9.16万元，增幅 4.02%。（数据宝） 京新药业1月12日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 财通证券股份有限公司新昌江滨西路证券营业部 | 2572.70 | 1102.18 | | 买二 | 深股通专用 | 2504.16 | 5869.63 | | 买三 | 中信证券股份有限公司浙江分公司 | 2024.26 | 88.47 | | 买四 | 中信建投证券股份有限公司宁波分公司 | 1820.12 | 2.09 | | 买五 | 浙商证券股份有限公司玉环长兴路证券营业部 | 1643.90 | 0.00 | | 卖一 ...

Core Viewpoint - On January 8, a total of 8 companies announced progress related to stock buybacks, with 5 companies disclosing ongoing buyback implementations and 3 companies completing their buyback plans [1] Group 1: Buyback Implementation Progress - The companies with the highest buyback amounts are Jian Sheng Group, Dongcheng Pharmaceutical, and Minsheng Health, with buybacks of 118 million, 17.1863 million, and 14.9993 million respectively [1] - As of January 8, 29 buyback plans have been completed this year, involving 22 companies, with 7 companies having completed buybacks exceeding 100 million [1] Group 2: Completed Buybacks - The companies that completed buybacks exceeding 10 million on that day are Jingxin Pharmaceutical, Huachangda, and Shibu Detection, with completed buybacks of 609 million, 41.8996 million, and 31.9512 million respectively [1] - The leading companies in terms of completed buyback amounts are BOE Technology Group, Jingxin Pharmaceutical, and New Hualian, with completed buybacks of 1.5 billion, 609 million, and 556 million respectively [1]

Core Viewpoint - The company has approved a share repurchase plan aimed at using its own funds to buy back shares for employee stock ownership plans and equity incentives, with a total repurchase amount adjusted to between RMB 35 million and RMB 70 million [2] Group 1: Share Repurchase Plan - The initial share repurchase plan was set for a total amount of no less than RMB 20 million and no more than RMB 40 million, with a maximum repurchase price of RMB 14.80 per share, allowing for an estimated repurchase of approximately 13.51 million to 27.03 million shares [1] - The total repurchase amount was later adjusted to a range of RMB 35 million to RMB 70 million, while other aspects of the repurchase plan remained unchanged [2] - The maximum repurchase price was subsequently adjusted to RMB 14.47 per share, allowing for an estimated repurchase of approximately 24.19 million to 48.38 million shares [3] Group 2: Implementation Status - As of the announcement date, the company completed the share repurchase plan, having repurchased a total of 47.27 million shares, which is 5.49% of the total share capital, with a total expenditure of RMB 608.72 million [4] - The highest purchase price during the repurchase was RMB 14.41 per share, and the lowest was RMB 11.86 per share [4] - The company confirmed that the actual repurchase funds exceeded the lower limit of the initial plan but did not exceed the upper limit, and the repurchase price remained within the set limits [5] Group 3: Compliance and Future Arrangements - The share repurchase was conducted in compliance with relevant regulations, ensuring that no shares were repurchased during periods that could significantly impact stock prices [6] - The repurchased shares will be stored in a dedicated account and will not have voting rights or profit distribution rights during the holding period [7] - If the shares are not utilized for the intended purposes within 36 months, the unused portion will be canceled following legal procedures [7]

Core Viewpoint - Jingxin Pharmaceutical (002020.SZ) has completed its share repurchase program, acquiring a total of 47.27 million shares, which represents 5.49% of the company's total share capital [1] Summary by Categories Share Repurchase Details - The company repurchased shares through a dedicated securities account via centralized bidding [1] - The highest purchase price for the shares was 14.41 CNY per share, while the lowest was 11.86 CNY per share [1] - The total amount spent on the repurchase was 608.72 million CNY, excluding transaction fees [1] Compliance and Strategy - The share repurchase complies with relevant laws and regulations [1] - The repurchase aligns with the company's established share repurchase plan [1]

每经AI快讯，京新药业1月7日晚间发布公告称，截至本报告披露日，公司回购股份期限已届满。公司 累计通过股份回购专用证券账户以集中竞价方式回购公司股份4,727.1295万股，占公司目前总股本的 5.49%，购买股份最高成交价为14.41元/股，购买股份最低成交价为11.86元/股，成交总金额为60,872.22 万元（不含交易费用）。本次回购符合相关法律法规的要求，符合公司既定的回购股份方案。 每经头条（nbdtoutiao）——十年首现，沪指连续站稳关键位置！高盛：建议高配中国股票！券商分析 师：人民币升值等因素加速跨境资本回流 （记者 曾健辉） ...

浙江京新药业股份有限公司（以下简称"公司"）于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 20,000 万元（含），不超过人民 币 40,000 万元（含），回购价格不超过 14.80 元/股（含），若按回购总金额上、 下限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年1月10日在《证券时报》《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于回购股份方案的公告》（公告编号：2025002）、《回购报告书》 （公告编号：2025003）。 证券代码：002020 证券简称：京新药业 公告编号：202600 ...

京新药业公告称，截至公告披露日，公司回购股份期限已届满，方案实施完毕。此次回购资金为自有资 金，累计回购股份4727.1295万股，占公司目前总股本的5.49%，成交总金额为6.09亿元（不含交易费 用），购买股份最高成交价为14.41元/股，最低成交价为11.86元/股。本次回购符合相关规定，股份将 用于股权激励或员工持股计划，若未使用将依法注销。 ...